Temporal trends and racial/ethnic- and sex-differences in LDL cholesterol control among US adults with self-reported atherosclerotic cardiovascular disease.

ASCVD LDL cholesterol Secondary prevention

Journal

American journal of preventive cardiology
ISSN: 2666-6677
Titre abrégé: Am J Prev Cardiol
Pays: Netherlands
ID NLM: 101769122

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 25 10 2023
revised: 31 03 2024
accepted: 15 04 2024
medline: 29 4 2024
pubmed: 29 4 2024
entrez: 29 4 2024
Statut: epublish

Résumé

Current guidelines for secondary prevention of atherosclerotic cardiovascular disease (ASCVD) recommend targeting a low-density lipoprotein cholesterol (LDL-C) of < 70 mg/dL. However, temporal trends and racial/ethnic- and sex-differences in achievement of LDL-C targets are not well described. We assessed trends and racial/ethnic- and sex-differences in achievement of LDL-C < 70 mg/dL using data from the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2008 to 2017-March 2020. We combined NHANES cycles into 4 periods: 2005-2008, 2009-2012, 2013-2016, and 2017-March 2020 and included participants ≥ 40 years with self-reported ASCVD. We estimated LDL-C < 70 mg/dL prevalence over time and further stratified by sex and race/ethnicity. We used multivariable logistic regression adjusted for social determinants of health and clinical covariates to model LDL-C target attainment. Among 1,826 NHANES participants representing 7,161,221 US adults with self-reported ASCVD (59.6% ≥ 65 years, 56.4% male, 74.8% White), LDL-C target attainment increased from 19.0% (95% CI, 15.3%-23.3%) in 2005-2008 to 26.3% (95% CI, 20.4%-33.1%) in 2017-March 2020 ( LDL-C control modestly improved between 2005 and 2008 and 2017-March 2020; however, only ∼1/4 of individuals met guideline-directed LDL-C treatment targets by 2017-March 2020. Women had lower LDL-C control and lesser magnitude of improvement in LDL-C control than men, highlighting a need for targeted interventions to improve lipid-lowering therapy utilization in this population.

Identifiants

pubmed: 38681067
doi: 10.1016/j.ajpc.2024.100673
pii: S2666-6677(24)00041-2
pmc: PMC11046243
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100673

Informations de copyright

© 2024 The Authors. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

Auteurs

Danh Q Nguyen (DQ)

Division of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.

Neil Keshvani (N)

Division of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.

Alvin Chandra (A)

Division of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.

Pamela L Alebna (PL)

VCU Health Pauley Heart Center, Richmond, VA, USA.

Dave L Dixon (DL)

VCU Health Pauley Heart Center, Richmond, VA, USA.
Department of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy, Richmond, VA, USA.

Michael D Shapiro (MD)

Section on Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Erin D Michos (ED)

Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Laurence S Sperling (LS)

Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA, USA.

Ambarish Pandey (A)

Division of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.

Anurag Mehta (A)

VCU Health Pauley Heart Center, Richmond, VA, USA.

Classifications MeSH